Core Insights - The latest net value of the Fuqua Precision Medical Mixed A fund is 2.9019 yuan, reflecting a growth of 3.48% [1] - The fund has shown significant performance with a one-month return of 18.27%, a three-month return of 30.86%, and a year-to-date return of 30.23%, ranking 8th out of 1502, 10th out of 1497, and 14th out of 1492 in its category respectively [1] Fund Holdings - The top ten stock holdings of the Fuqua Precision Medical Mixed A fund account for a total of 69.71%, with the largest positions being: - Baillie Gifford (9.66%) - Haisco (9.65%) - Kelun Pharmaceutical (9.10%) - Huatai Medical (9.05%) - Zai Lab (7.84%) - Heng Rui Medicine (5.95%) - Innovent Biologics (5.29%) - Sinovac Biotech (5.11%) - BeiGene (4.91%) - Zhaoke Pharmaceutical (3.15%) [1] Fund Management - The Fuqua Precision Medical Mixed A fund was established on November 16, 2017, and as of March 31, 2025, it has a total asset size of 3.746 billion yuan, managed by Zhao Wei [1]
4月22日富国精准医疗混合A净值增长3.48%，近3个月累计上涨30.86%
Sou Hu Cai Jing·2025-04-22 12:30